- Home
- CANF vs MVSTW Comparison
CANF vs MVSTW Comparison
Compare CANF & MVSTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- MVSTW
- Stock Information
- Founded
- CANF 1994
- MVSTW 2006
- Country
- CANF Israel
- MVSTW United States
- Employees
- CANF N/A
- MVSTW 2006
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- MVSTW Industrial Machinery/Components
- Sector
- CANF Health Care
- MVSTW Miscellaneous
- Exchange
- CANF Nasdaq
- MVSTW Nasdaq
- Market Cap
- CANF 7.9M
- MVSTW N/A
- IPO Year
- CANF N/A
- MVSTW N/A
- Fundamental
- Price
- CANF $1.20
- MVSTW $0.16
- Analyst Decision
- CANF Strong Buy
- MVSTW
- Analyst Count
- CANF 2
- MVSTW 0
- Target Price
- CANF $14.00
- MVSTW N/A
- AVG Volume (30 Days)
- CANF 413.8K
- MVSTW 126.0K
- Earning Date
- CANF 04-29-2025
- MVSTW 03-14-2025
- Dividend Yield
- CANF N/A
- MVSTW N/A
- EPS Growth
- CANF N/A
- MVSTW N/A
- EPS
- CANF N/A
- MVSTW N/A
- Revenue
- CANF $674,000.00
- MVSTW $370,989,000.00
- Revenue This Year
- CANF $461.72
- MVSTW N/A
- Revenue Next Year
- CANF N/A
- MVSTW N/A
- P/E Ratio
- CANF N/A
- MVSTW N/A
- Revenue Growth
- CANF N/A
- MVSTW 39.03
- 52 Week Low
- CANF $1.22
- MVSTW $0.35
- 52 Week High
- CANF $4.69
- MVSTW $0.44
- Technical
- Relative Strength Index (RSI)
- CANF 37.12
- MVSTW N/A
- Support Level
- CANF $1.22
- MVSTW N/A
- Resistance Level
- CANF $1.82
- MVSTW N/A
- Average True Range (ATR)
- CANF 0.13
- MVSTW 0.00
- MACD
- CANF -0.02
- MVSTW 0.00
- Stochastic Oscillator
- CANF 3.13
- MVSTW 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.